87N.F STEVANATO GROUP SPA O.N.
- Market cap
- EUR 3.41B
- P/E
- 24.5x
- P/B
- 2.06x
- ROE
- 7.8%
- Dividend yield
- 0.43%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 87N.F undervalued?
Graham number87N.F trades 49.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STEVANATO GROUP SPA O.N. fundamental analysis
No fundamental analysis for STEVANATO GROUP SPA O.N. yet.
STEVANATO GROUP SPA O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STEVANATO GROUP SPA O.N.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic s…
Full company profileSTEVANATO GROUP SPA O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STEVANATO GROUP SPA O.N. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 844M | 984M | 1.09B | 1.10B | 1.19B | 1.20B |
| Gross Profit | 265M | 320M | 340M | 302M | 344M | 343M |
| Operating Income | 162M | 192M | 201M | 161M | 199M | 201M |
| EBITDA | - | 256M | 272M | 248M | 284M | 224M |
| Net Income | 134M | 143M | 146M | 118M | 140M | 124M |
| EPS | 0.51 | 0.54 | 0.55 | 0.43 | 0.51 | 0.45 |
| Balance Sheet | ||||||
| Total Assets | 1.42B | 1.66B | 2.07B | 2.33B | 2.54B | 2.67B |
| Total Liabilities | 577M | 664M | 939M | 924M | 1.06B | 1.07B |
| Shareholders' Equity | 842M | 996M | 1.13B | 1.40B | 1.49B | 1.59B |
| Cash & Short-term Investments | 411M | 229M | 69.6M | 98.3M | 131M | 115M |
| Cash Flow | ||||||
| Operating Cash Flow | 133M | 103M | 105M | 156M | 286M | 220M |
| Capital Expenditure | 113M | 243M | 442M | 314M | 275M | 230M |
| Free Cash Flow | 20.2M | -140M | -337M | -158M | 11.0M | -10.3M |
| Ratios | ||||||
| ROE | 16.0% | 14.3% | 12.9% | 8.4% | 9.4% | 7.8% |
| ROA | 9.5% | 8.6% | 7.0% | 5.1% | 5.5% | 4.6% |
| Net Profit Margin | 15.9% | 14.5% | 13.4% | 10.7% | 11.8% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
STEVANATO GROUP SPA O.N. dividends
- Dividend yield
- 0.43%
- Forward dividend
- 0.05 EUR
- Payout ratio
- 10.5%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 14.7M | 0.05 | 10.5% |
| 2024 | EUR 14.5M | 0.05 | 12.3% |
| 2023 | EUR 14.3M | 0.05 | 9.8% |
| 2022 | EUR 13.5M | 0.05 | 9.5% |
| 2021 | EUR 11.2M | 0.04 | 8.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns STEVANATO GROUP SPA O.N.
- Insiders 1.78%
- Institutions 98.22%
- Public & others 0.00%
- Shares outstanding 49.8M
- Free float 49.0M
STEVANATO GROUP SPA O.N. company profile
- Company name
- STEVANATO GROUP SPA O.N.
- Ticker
- 87N.F
- ISIN
- IT0005452658
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6,010
- Fiscal year end
- December
- Address
- Via Molinella 17, Piombino Dese, PD, Italy, 35017
- Phone
- 39 04 99 31 811
- Website
- stevanatogroup.com
About STEVANATO GROUP SPA O.N.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
STEVANATO GROUP SPA O.N. management
5- Mr. Franco StevanatoCEO & Executive Chairman · born 1973
- Mr. Marco Dal LagoChief Financial Officer · born 1973
- Ms. Lisa MilesChief Communications & Investor Relations Officer
- Ms. Carla CostaChief Human Resources Officer
- Mr. Michele MonicoPresident of DDS & IVD Business Unit